Is wellness your goal? Use our exclusive iHerb code to save on vitamins, supplements and more
Is wellness your goal? Use our exclusive iHerb code to save on vitamins, supplements and more Shop daily vitamins, top-rated supplements, protein powders and more.
We're way beyond New Year's resolutions (which are all obviously going great, right?), but there's always room for improvement when it comes to our overall health. I recently started a health journey of my own, which has included a myriad of supplements. Seriously, the vitamin collection in my pantry is starting to look like a Walgreens aisle. But, I can't brag enough about the benefits, like preventing migraines with a magnesium supplement or giving my hair and skin a serious boost with vitamin D capsules.
If you're interested in building up your own collection health and wellness-focused goodies, iHerb can help.
Right now, you can save up to 25% on your first iHerb order of $60 or more when you use our exclusive promo code, BLOOM25, at checkout. If it's not your first iHerb order, you can save on orders of $60 or more when you use the exclusive promo code, BLOOM15, at checkout.
Here's what you need to know about iHerb, and a look at some of their top deals:
BEAT THE SNIFFLES: Struggling with spring allergies? DoorDash can deliver relief the same day the sniffles strike
iHerb's best-selling vitamins and supplements
Use coupon codes BLOOM15 or BLOOM25 to save. These exclusive USA TODAY Shopping codes cannot be combined with any other offers on the website.
Quest Nutrition, Protein Powder, Salted Caramel
California Gold Nutrition - Vitamin C
Doctor's Best, High Absorption Magnesium
California Gold Nutrition, CollagenUP®
California Gold Nutrition, Sport, Creatine Monohydrate
More: Men can easily manage weight loss, hair growth and sexual wellness with Hims
What is iHerb?
iHerb specializes in health and wellness products, like vitamins, supplements, protein and more. You can shop in top categories like supplements, sports, bath, beauty, baby and pets. That's right, you can focus on the health and wellness of your entire family, including Fido, at iHerb.
Save up to 25% at iHerb today
What makes iHerb different?
iHerb sells over 50,000 different brand name products at low prices with fast shipping. Here are the other key benefits that to shopping at iHerb:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
EHTH Q1 Earnings Call: Revenue Growth, Margin Expansion, and Regulatory Developments Shape Outlook
Online health insurance comparison site eHealth (NASDAQ:EHTH) announced better-than-expected revenue in Q1 CY2025, with sales up 21.7% year on year to $113.1 million. The company expects the full year's revenue to be around $530 million, close to analysts' estimates. Its non-GAAP loss of $0.27 per share was 38.1% above analysts' consensus estimates. Is now the time to buy EHTH? Find out in our full research report (it's free). Revenue: $113.1 million vs analyst estimates of $99.72 million (21.7% year-on-year growth, 13.4% beat) Adjusted EPS: -$0.27 vs analyst estimates of -$0.43 (38.1% beat) Adjusted EBITDA: $12.52 million vs analyst estimates of -$7.99 million (11.1% margin, significant beat) The company reconfirmed its revenue guidance for the full year of $530 million at the midpoint EBITDA guidance for the full year is $47.5 million at the midpoint, above analyst estimates of $46.01 million Operating Margin: 4.2%, up from -19.3% in the same quarter last year Estimated Membership: 1.16 million, down 21,363 year on year Market Capitalization: $125.6 million eHealth's first quarter performance was shaped by significant Medicare enrollment activity and continued optimization of its sales and marketing operations. CEO Fran Soistman highlighted a 22% increase in Medicare submissions, emphasizing the impact of targeted marketing and enhanced telephonic and online conversion rates. The company attributed margin improvement to efficiency gains and lower acquisition cost per approved member, despite doubling the size of its retention and customer service team. Management also referenced the positive effects of omnichannel capabilities and a brand strategy resonating with Medicare beneficiaries. The integration of AI into the telephonic enrollment process and robust cash collections from new enrollments contributed to profitability gains. Soistman noted, 'Our omnichannel marketplace empowered hundreds of thousands of Medicare beneficiaries to explore their coverage choices, a complicated and highly consequential decision.' Looking ahead, eHealth's guidance is grounded in an evolving regulatory landscape and shifting Medicare Advantage reimbursement rates. Management pointed to the finalization of new Medicare rules and increased carrier reimbursement rates as important developments for the industry, while remaining cautious about predicting the impact on the next enrollment period. Soistman stated, 'While we have seen positive early signs of the Medicare macro environment thus far in the year, it is too early to tell how this upcoming enrollment cycle... will compare to last year's.' The company identified new-to-Medicare enrollments and regulatory changes around special needs plans as key focus areas for the next two quarters. eHealth also addressed the recent Department of Justice complaint, affirming its intent to defend its practices and emphasizing no current impact on operations or carrier relationships. These factors, along with further investments in technology and brand development, are expected to shape the trajectory for the remainder of the year. Management attributed strong quarterly results to Medicare enrollment growth, cost efficiencies, and the integration of new technology, while also addressing evolving regulatory and legal developments. Medicare enrollment momentum: eHealth achieved 22% growth in total Medicare submissions, driven by targeted marketing campaigns and improvements in both telephonic and online conversion rates. The company's omnichannel approach, including hybrid online-agent enrollments, saw particularly high growth, reflecting consumer demand for flexible shopping and advisory options. Operational efficiency gains: Despite nearly doubling the size of the retention and customer service team, acquisition cost per approved Medicare member declined by 10% year over year. This was credited to a greater proportion of leads from direct branded channels and ongoing process improvements in customer acquisition and retention efforts. Technological advancements: eHealth initiated a pilot program integrating artificial intelligence into its telephonic enrollment process. Early results indicate the technology provides valuable after-hours support and reduces wait times during peak enrollment periods. Management plans further investment in AI capabilities ahead of the annual enrollment period (AEP). Regulatory clarity and industry environment: The company welcomed recent final Medicare Advantage and prescription drug plan rules, as well as higher-than-anticipated carrier reimbursement rates for 2026. Leadership views these developments as supportive for both brokers and beneficiaries but noted it is premature to forecast the impact on next cycle's commission rates and plan offerings. Legal and compliance update: Management addressed the Department of Justice complaint regarding industry practices, stating the company is fully cooperating and believes the claims are without merit. They reported no change in operations or carrier relationships as a result, and no litigation reserve has been recorded. Management expects future performance to be shaped by regulatory developments, Medicare enrollment trends, and ongoing investments in technology and brand initiatives. Regulatory changes and reimbursement rates: eHealth anticipates that new Medicare Advantage rules and updated carrier reimbursement rates will influence plan offerings, beneficiary shopping activity, and broker commission structures in the next enrollment cycle. However, leadership remains cautious, noting that the full effect will not be clear until carrier bids and CMS commission rates are finalized in coming months. Enrollment seasonality and member retention: Changes in dual special needs plan (D-SNP) enrollment rules are expected to create year-over-year headwinds in the second and third quarters. Management is focused on capturing new-to-Medicare customers and improving retention, particularly among members who switch plans but remain with eHealth. Early indicators suggest improved recapture rates, though full retention metrics will be available later in the year. Technology and brand investments: The company continues to invest in AI-powered enrollment tools, omnichannel platform enhancements, and expanded brand campaigns. These initiatives are intended to support advisor productivity, increase consumer trust, and drive higher conversion rates during critical enrollment periods. Management believes these efforts will help differentiate eHealth in a competitive landscape. Going forward, the StockStory team will be monitoring (1) the pace of Medicare enrollment growth, especially among new-to-Medicare beneficiaries during off-cycle periods; (2) the impact of regulatory and reimbursement changes on plan availability, consumer behavior, and broker commissions; and (3) any developments related to the Department of Justice investigation and its effect on carrier relationships. Progress in technology deployment and brand expansion will also be important markers of effective execution. eHealth currently trades at a forward EV/EBITDA ratio of 2.7×. In the wake of earnings, is it a buy or sell? Find out in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
Hims & Hers Health, Inc. (HIMS) closed at $55.25 in the latest trading session, marking a -2.83% move from the prior day. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Coming into today, shares of the company had gained 2.99% in the past month. In that same time, the Medical sector gained 3.49%, while the S&P 500 gained 6.29%. Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's upcoming EPS is projected at $0.17, signifying a 183.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $551.84 million, up 74.83% from the year-ago period. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.73 per share and a revenue of $2.34 billion, representing changes of +170.37% and +58.31%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.66% upward. Hims & Hers Health, Inc. is currently a Zacks Rank #2 (Buy). From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 77.39. This valuation marks a premium compared to its industry's average Forward P/E of 27.09. Meanwhile, HIMS's PEG ratio is currently 2.12. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Info Systems industry had an average PEG ratio of 2.12 as trading concluded yesterday. The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 70, which puts it in the top 29% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Eli Lilly telehealth deals to prevent sale of compounded GLP-1s
Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not being sold on these sites. Yahoo Finance senior health reporter Anjalee Khemlani sheds more light on this and compares other GLP-1 manufacturers' telehealth deals. Also watch Anjalee Khemlani's coverage of US Health Secretary Robert F. Kennedy, Jr.'s decision to remove all 17 members of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Eli Lilly revealing a caveat to its agreement with telehealth firms including its recent deals with Ro and LifeMD. Yahoo! Finance's Anjalee Khemlani joining us now with more. So tell us more about this caveat, Anj. Bloomberg reported some details about Eli Lilly's agreements with these telehealth companies, and that includes, as you mentioned, some of the ones that are not the big names we know. So not Hims & Hers, and that is sort of the point of this mention, that Lilly has created a route to be able to get their product in with these companies, while also ensuring that the compounded versions are not being sold on the same site and they're not competing with those compounded versions. Important to note though, and we got a statement from Eli Lilly that they are actually helping their competitor Novo Nordisk out, because in the comment I got, it said quote, 'Anyone continuing to sell mass compounded tirzepatide or semaglutide products including by referring to them as personalized, tailored or something similar is breaking the law.' That's a direct quote from Eli Lilly, and the call out on personalized and tailored is because that is a loophole that certain compounded pharmacies are currently trying to use to keep these compounded GLP-1s on the market, saying that they don't entirely have to shut down despite the FDA bringing those products off the shortage list and therefore stopping compounded products. Now, this is interesting because we have seen a number of telehealth companies, not just partner with Eli Lilly, but also Novo Nordisk and their telehealth platform. And Hims & Hers is currently partnered with Novo Nordisk. So it seems that that caveat was not part of the agreement there. So two different sort of competing strategies to try and compete with compounded products and get them off the market, or not at all in the case of Novo Nordisk. But this is the reason why that Lilly caveat is so interesting. There are some companies that are part of the platform that do continue to sell compounded products, and it remains to be seen how Lilly does manage those and how they go after them. Anj, I'm just going to put a fine point on it, Hims & Hers, I'm looking at the shares are down about 3%, and it looks like it is indeed linked to this. Of course, Hims & Hers is also up, like, 128% this year. That's right, yes, they definitely have been benefiting from the GLP-1 boost, and one of the biggest ones that we can track as a publicly traded company. And that's sort of the benefit that they've had is that no matter what has been happening in GLP plus telehealth world, they have been the benefactors of that in their stock price. And now to this point when the sort of mask is taken off on, on some of these agreements, it comes down to whether or not Hims decides to join the, the entire rest of the community and the other telehealth players in taking down these compounded products or whether or not they continue to sell them. I did speak to previously one of the telehealth companies, and they said that they had given their members a chance to buy sort of a year's worth of supply of compounded products by the deadline, and some clients did take advantage of that. So there clearly is still a market for these products based on their price, and who's trying to, you know, access them, but it seems like the companies are working with the authorities to try and do a better job of policing that and see, and making sure that the branded products are the ones now on the market. Anj, thanks, as always, for your coverage of the GLP-1 space, appreciate it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
